Towards this goal, c-Myc amplification in a genetic model of PIK3CA-related breast cancer was discovered to circumvent PI3K-targeted treatment, in agreement with the observation that high MYC levels aligned with mutation of PIK3CA in patient samples (Liu et al., 2011). The gene discussed is MYC; the disease is breast carcinoma.